GLP-1 Postmarket Safety Signals Intensify

UK MHRA reports 216 deaths linked to tirzepatide, semaglutide, liraglutide; Caroline Savage inquest highlights fecal peritonitis risk. This adds to ongoing postmarket surveillance concerns including NAION, alopecia, and compounded risks. The risk-benefit debate continues as use expands.